Sveinn Sölvason, President and CEO, comments:

"Sales in Q3 2025 amounted to USD 237 million, representing 11% reported growth, of which 7% was organic.

Growth picked up in the third quarter as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. The solid momentum in EMEA continues and growth in Americas was strong following a soft start to the year, supported by our recently launched innovations.

The EBITDA margin was strong at 22% in Q3 2025 and 21% for the first nine months of the year compared to 20% (before special items) in the comparable period. In line with our performance recorded in the first nine months of 2025, our guidance for the full-year 2025 has been reiterated"

Embla will host a conference call on Oct 21, 2025 at 09:00 CET / 7:00 GMT / 3:00 ET.

To participate in the telephone conference please use the dial-in details provided below:
DK: +45 78 76 84 90
SE: +46 31-311 50 03
UK: +44 20 3769 6819
US: +1 646 787 0157
Participant access code: 274982

The webcast will be available through the following link: Embla Medical Q3 2025 webcast.

• Download Company Announcement
• Download Investor Presentation